Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination With KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects

NCT00244712 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00244712
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00244712 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination With KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2005
Completion date
April 30, 2008
Enrollment
688 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection